This week the regulatory architecture of Latin American clinical research shifted in a way that has been three years in the making. Brazil's Law 14.874/2024 entered full force, Mexico opened a targeted acceleration lane
first-in-human · clinical trial · clinical research · regulatory · ANVISA · ANMAT
This week the regulatory architecture of Latin American clinical research shifted in a way that has been three years in the making. Brazil's Law 14.874/2024 entered full force, Mexico opened a targeted acceleration lane for clinical trials, and the Pan American Health Organization moved its Clinical Trial Accelerator from press event to working program. Two competitive signals -- a Portuguese Phase I unit positioning itself as a Brazil bridge, and the FDA's new Real-Time Clinical Trials pilot -- mark the boundaries of what the region now has to defend.
Brazil activates a 90-day cap, parallel review, and tacit approval -- in a single framework
Mexico pilots accelerated COFEPRIS clinical trial reviews, distinct from commercial reliance
PAHO's Clinical Trial Accelerator turns operational with adaptive trials seminars
Argentina's 62-day cap is still awaiting its first empirical readout
Astrum Porto markets itself as an ANVISA-certified bridge into LATAM submissions
The FDA launches a Real-Time Clinical Trials pilot that will reshape site expectations
Take a closer look at where first-in-human work is now le
Brazil Activates Its New Clinical Trial Framework
Brazil's Law 14.874/2024 entered full force on April 28, 2026, ending the 12-month implementation window and producing the most consequential regulatory event in Latin American clinical research this year. The law combines a 90-business-day statutory cap on ANVISA review, parallel ANVISA and ethics review, a tacit approval mechanism when deadlines are missed, and the removal of CONEP as a first-instance reviewer for international sponsors. Class I and II device first-in-human trials still proceed under the existing CEP-only carve-out from RDC 837/2023.
Why It Matters: This is the first time a Latin American country has integrated speed, predictability, and enforcement into a single framework. If ANVISA holds the 90-day timeline in practice, Brazil moves from historically slower jurisdiction to the regional leader for first-in-human and early-phase studies. First empirical timeline data from sponsors submitting on or after April 28 should emerge in late July or early August.
Mexico Pilots Faster Clinical Trial Reviews
Mexico has introduced a targeted acceleration mechanism through a COFEPRIS prioritized review pilot for clinical trials. Unlike the agency's existing reliance pathway tied to commercial registration, this initiative is focused specifically on clinical trial approvals. Eligibility criteria and review timelines have not yet been disclosed, but the direction is unambiguous: Mexico is choosing selective acceleration over wholesale system reform.
Bottom Line: In the near term, the pilot preserves Mexico's role as a tactical option for sponsors seeking faster entry into early-phase trials -- particularly for studies with high public-health value or designated breakthrough mechanisms. Sponsors should monitor for COFEPRIS official guidance on eligibility and targe
PAHO's Accelerator Moves From Launch to Execution
Less than four weeks after the April 9 launch of the Clinical Trial Accelerator, the Pan American Health Organization is now running its operational seminar series. The latest session focuses on adaptive and platform trial design, examining the ethical, regulatory, and operational implications of these methodologies for Latin American sites. The shift from coordination to enablement is significant: it positions PAHO as the agency translating regional reform into protocol-level practice.
What to Focus On: Adaptive and platform trials are exactly the type of complex protocol that has historically been hard to implement in Latin America. PAHO's working agenda suggests the region is preparing the institutional groundwork to support more sophisticated study designs -- a prerequisite for sponsors moving from single-country first-in-human studies to multi-country pivotal programs.
Advance Your First-in-Human Trials with Confidence
bioaccess® is the world's only CRO dedicated exclusively to first-in-human clinical trials in Latin America, helping MedTech, biopharma, and radiopharma sponsors compress timelines and reduce cost without compromising regulatory rigor.
Country-aware pathway design across Argentina, Brazil, Colombia, Mexico, Panama, Bolivia, and other LATAM jurisdictions
End-to-end execution from regulatory submission through site activation, EDC, and monitoring
Direct, founder-led engagement built around the timelines startups actually face
Schedule your first-in-human trial consultation at
Argentina's 62-Day Promise Enters Its First Real Test
Argentina's Disposicion 7516/2025, the rule that capped ANMAT clinical trial reviews at 62 calendar days, has been operative since December 1, 2025. Trials submitted in the first weeks of the new regime should have completed the cycle by late February or March, which means Q2 2026 should already have delivered the first meaningful comparison between the statutory clock and the operational one. As of this week, no empirical data has been published. The framework remains one of the most ambitious in the region, but five weeks past the first eligible cohort, the absence of confirmed timelines is its own data point.
Bottom Line: Argentina remains a high-potential option for first-in-human trials, but until ANMAT publishes Q2 actual approval times, sponsors evaluating the country are working with a regulatory promise rather than a regulatory record.
Astrum Porto Markets Itself as a Bridge Into LATAM Submissions
Astrum's Phase I unit in Porto, Portugal, holds ANVISA certifications from 2023 and 2025 in addition to FDA, EMA, NPRA, and GCC accreditations. The company is now actively marketing itself as a single site that can support regulatory submissions across Europe, the United States, Brazil, and the wider Latin American region. The proposition: generate Brazil-submittable data without operating in Brazil.
Why It Matters: This is a real competitive dynamic for the region's CRO and site networks. Geography has become more flexible. For sponsors, Astrum lowers execution risk on early phases at the cost of distance from local patient populations and country-specific regulatory experience. For LATAM operators, it means competing on operational depth, regulatory familiarity, and patient access -- not just on whether data is technically eligible
The FDA's Real-Time Clinical Trials Pilot Resets Site Expectations
The U.S. Food and Drug Administration announced its Real-Time Clinical Trials pilot on April 28, with two proof-of-concept studies already underway: AstraZeneca's Phase 2 TRAVERSE (mantle cell lymphoma) and Amgen's Phase 1b STREAM-SCLC. The model is built on continuous data capture, ongoing monitoring, and rapid decision-making, and a request for information on broader expansion is open through May 29. For Latin American sites participating in FDA-regulated programs, the pilot signals a structural shift: speed of activation will remain important, but the ability to deliver high-quality, near real-time data may become equally critical to site selection.
What to Focus On: Sponsors selecting LATAM sites for FDA-regulated trials should evaluate not only regulatory turnaround but also site infrastructure for continuous data capture, EDC integration depth, and monitoring cadence. The next round of competitive differentiation in the region is likely to be operational, not regulatory.
Key Takeaways
Brazil's Law 14.874/2024 went into full force April 28, combining a 90-day cap, parallel review, tacit approval, and CONEP elimination -- the most consequential LATAM clinical research event of 2026.
Mexico's COFEPRIS prioritized review pilot signals a selective acceleration lane for clinical trials, distinct from existing commercial reliance pathways.
PAHO's Clinical Trial Accelerator is now an operating program, with a working seminar series focused on adaptive and platform trial design.
Argentina's 62-day cap remains untested in the data; five weeks past the first eligible cohort, ANMAT has not yet published empirical approval timelines.
Astrum Porto's ANVISA-certified Phase I unit introduces a new competitive dynamic for LATAM CROs, marketing itself as a bridge into Brazilian and regional submissions.
The FDA's Real-Time Clinical Trials pilot will reshape what sponsors expect of site infrastructure, raising the bar for continuous data capture alongside speed of activation.
: https://www.linkedin.com/company/bioaccessla
← All Global Trial Accelerators editions · Contact bioaccess®